1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Orticumab : the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy
- Contribution to journal › Scientific review
- 2024
-
Mark
Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial
(2024) In Cardiovascular Research
- Contribution to journal › Article